{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:04:37Z","timestamp":1760853877464,"version":"3.41.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1984,5,1]],"date-time":"1984-05-01T00:00:00Z","timestamp":452217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[1984,5]]},"DOI":"10.1016\/s0025-7125(16)31127-0","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:17:24Z","timestamp":1459988244000},"page":"757-787","source":"Crossref","is-referenced-by-count":47,"title":["Multiple Myeloma"],"prefix":"10.1016","volume":"68","author":[{"given":"Martin M.","family":"Oken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0025-7125(16)31127-0_bib0005","first-page":"1273","article-title":"Phase III Study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus melphalan and prednisone in myeloma","volume":"66","author":"Abramson","year":"1982","journal-title":"Cancer Treat. Rep"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cpt1979266737","article-title":"Oral melphalan kinetics","volume":"26","author":"Alberts","year":"1979","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","article-title":"Localized and indolent myeloma","volume":"58","author":"Alexanian","year":"1980","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0020","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I","article-title":"Prognostic factors in multiple myeloma","volume":"36","author":"Alexanian","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","article-title":"Remission maintenance therapy for multiple myeloma","volume":"135","author":"Alexanian","year":"1975","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0030","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C","article-title":"Combination chemotherapy for multiple myeloma","volume":"30","author":"Alexanian","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0035","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO;2-1","article-title":"Chemotherapy for multiple myeloma","volume":"53","author":"Alexanian","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0040","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","article-title":"Unmaintained remissions in multiple myeloma","volume":"51","author":"Alexanian","year":"1978","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0045","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma","volume":"208","author":"Alexanian","year":"1969","journal-title":"J.A.M.A"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0050","first-page":"225","article-title":"Normal immunoglobulins in multiple myeloma: Effect of melphalan chemotherapy","volume":"75","author":"Alexanian","year":"1970","journal-title":"J. Lab. Clin. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0055","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X","article-title":"Combination therapy for multiple myeloma","volume":"40","author":"Alexanian","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0060","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/1097-0142(19810415)47:8<1923::AID-CNCR2820470802>3.0.CO;2-Z","article-title":"Chemoimmunotherapy for multiple myeloma","volume":"47","author":"Alexanian","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian","year":"1983","journal-title":"Blood"},{"year":"1978","key":"10.1016\/S0025-7125(16)31127-0_bib0070","article-title":"Manual for Staging of Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.0954-6820.1966.tb05453.x","article-title":"Frequency of pathological proteins (M-components) in 6995 sera from an adult population","volume":"179","author":"Axelsson","year":"1966","journal-title":"Acta Med. Scand"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0308-2261(21)00324-6","article-title":"Localized plasmacytomas","volume":"11","author":"Bataille","year":"1982","journal-title":"Clin. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0085","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/1097-0142(19810801)48:3<845::AID-CNCR2820480330>3.0.CO;2-E","article-title":"Solitary myeloma: Clinical and prognostic features of a review of 114 cases","volume":"48","author":"Bataille","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.1983.1.8.510","article-title":"Progress in the treatment of plasma cell myeloma?","volume":"1","author":"Bergsagel","year":"1983","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0095","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy of plasma cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/archinte.1975.00330010174022","article-title":"Treatment of plasma cell myeloma with cytotoxic agents","volume":"135","author":"Bergsagel","year":"1975","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0105","series-title":"Cancer: Principles and Practice of Oncology","article-title":"Plasma cell neoplasms","author":"Bergsagel","year":"1982"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0110","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/archinte.1982.00340250041008","article-title":"Reversible renal insufficiency in multiple myeloma","volume":"142","author":"Bernstein","year":"1982","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0115","series-title":"Progress in Myeloma: Biology of Myeloma","article-title":"Epidemiology of multiple myeloma and related plasma cell disorders: An analytic review","author":"Blattner","year":"1980"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0120","series-title":"Cancer Epidemiology and Prevention","article-title":"Multiple myeloma and macroglobulinemia","author":"Blattner","year":"1982"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0125","first-page":"1267","article-title":"Vincristine, BCNU, doxorubicin and prednisone (VBAP) combination in the treatment of relaping or resistant multiple myeloma: A Southwest Oncology Group study","volume":"66","author":"Bonnet","year":"1982","journal-title":"Cancer Treat. Rep"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0130","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archinte.1982.00340190200039","article-title":"Decreasing M-spike with increasing tumor burden in multiple myeloma [Letter]","volume":"142","author":"Bouvet","year":"1982","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0135","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1084\/jem.158.5.1769","article-title":"A tumor-associated antigen specificfor human kappa myeloma cells","volume":"158","author":"Boux","year":"1983","journal-title":"J. Exp. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0140","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJM197510302931801","article-title":"Impaired synthesis of polyclonal (non para protein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma; role of suppressor cells","volume":"293","author":"Broder","year":"1975","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0145","first-page":"237","article-title":"Cisplatin, BCNU, cyclophosphamide and prednisone in multiple myeloma","volume":"66","author":"Broun","year":"1982","journal-title":"Cancer Treat. Rep"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0150","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0155","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0002-9343(77)90543-5","article-title":"Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol","volume":"63","author":"Case","year":"1977","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0160","first-page":"145","article-title":"Proposed guidelines for protocol studies-II. Plasma cell myeloma","volume":"4","year":"1973","journal-title":"Cancer Chemother. Rep"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00000421-198202000-00004","article-title":"Hexamethylmelamine and prednisone in the treatment of refractory myeloma","volume":"5","author":"Cohen","year":"1982","journal-title":"Am. J. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.1975.00330010179023","article-title":"Managing the complications of plasma cell myeloma","volume":"135","author":"Cohen","year":"1975","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0175","first-page":"406","article-title":"Unmaintained remission after two years of combination chemotherapy in myeloma","volume":"20","author":"Cohen","year":"1979","journal-title":"Proc. Am. Assoc. Cancer Res. and Am. Soc. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood.V54.4.824.824","article-title":"Combination chemotherapy with intermittent 1-3-bis (2-chloroethyl) 1-nitrosourea (BCNU), cyclophosphamide and prednisone for multiple myeloma","volume":"54","author":"Cohen","year":"1979","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0185","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/1097-0142(19820401)49:7<1328::AID-CNCR2820490703>3.0.CO;2-4","article-title":"Whole bone marrow irradiation for the treatment of multiple myeloma","volume":"49","author":"Coleman","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0190","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/archinte.1975.00330010141018","article-title":"Clinical classification of plasma cell myeloma","volume":"135","author":"Conklin","year":"1975","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0195","first-page":"399","article-title":"Hypersensitivity reactions to IV melphalan during treatment of multiple myeloma. Cancer and Leukemic Group B experience","volume":"63","author":"Cornwell","year":"1979","journal-title":"Cancer Treat.Rep"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0002-9343(73)90116-2","article-title":"Melphalan and prednisone. An effective combination for the treatment of multiple myeloma","volume":"54","author":"Costa","year":"1973","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0205","article-title":"The Third National Cancer Survey: Incidence Data","volume":"42","author":"Cutler","year":"1975","journal-title":"Natl. Cancer Inst. Monogr"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0210","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJM198101223040404","article-title":"Radiation-induced myelomatosis","volume":"304","author":"Cuzik","year":"1981","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.0954-6820.1979.tb06026.x","article-title":"Paraplegia in myelomatosis-A study of 20 cases","volume":"205","author":"Dahlstrom","year":"1979","journal-title":"Acta Med. Scand"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00005792-197803000-00003","article-title":"Renal function in patients with multiple myeloma","volume":"57","author":"DeFronzo","year":"1978","journal-title":"Medicine"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0225","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005792-197505000-00003","article-title":"Acute renal failure in multiple myeloma","volume":"54","author":"DeFronzo","year":"1975","journal-title":"Medicine"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0230","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2141.1981.tb02730.x","article-title":"Peripheral neuropathy and plasma cell neoplasias: A report of 10 cases","volume":"48","author":"Delauche","year":"1981","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajh.2830130406","article-title":"Nonsecretory multiple myeloma","volume":"23","author":"Dreicer","year":"1982","journal-title":"Am. J. Hematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0240","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V57.2.333.333","article-title":"The growth fraction of human myeloma cells","volume":"57","author":"Drewinko","year":"1981","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0245","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/archinte.1979.03630450038013","article-title":"Plasma cell neoplasms with osteoclerotic lesions: A study of five cases and a review of the literature","volume":"239","author":"Driedger","year":"1979","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0308-2261(21)00319-2","article-title":"Staging and kinetics of multiple myeloma","volume":"22","author":"Durie","year":"1982","journal-title":"Clin. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2141.1981.tb02757.x","article-title":"Synthesis and metabolism of Bence-Jones protein and calculation of tumor burden in patients with Bence-Jones myeloma","volume":"47","author":"Durie","year":"1981","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0260","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(80)92941-4","article-title":"Reappraisal of plateau phase in myeloma","volume":"2","author":"Durie","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0265","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma1","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0308-2261(21)00327-1","article-title":"The current status and future prospects of treatment for multiple myeloma","volume":"11","author":"Durie","year":"1982","journal-title":"Clin. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0275","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V55.3.364.364","article-title":"Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma","volume":"55","author":"Durie","year":"1980","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0280","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2141.1981.tb02758.x","article-title":"Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma","volume":"47","author":"Durie","year":"1981","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0285","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-3083.1977.tb00409.x","article-title":"Immunoglobulins in families of myeloma patients","volume":"6","author":"Festen","year":"1977","journal-title":"Scand. J. Immunol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0290","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/1097-0142(19830101)51:1<166::AID-CNCR2820510132>3.0.CO;2-7","article-title":"Anaplastic myeloma with massive extra medullary involvement. Report of two cases","volume":"51","author":"Foucar","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0295","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.1982.03330150061026","article-title":"Aggressive phase of multiple myeloma with pulmonary plasma cell infiltrates","volume":"248","author":"Garewal","year":"1982","journal-title":"J.A.M.A"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0300","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.1984.2.1.51","article-title":"Serum betaa-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders","volume":"2","author":"Garewal","year":"1984","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0009-9260(70)80138-6","article-title":"Special myeloma and cord compression: Diagnosis and management","volume":"21","author":"Garrett","year":"1970","journal-title":"Clin. Radiol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0310","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/jnci\/52.4.1199","article-title":"Quantitation of total-body tumor cells (MOPC 104E). 1. Subcutaneous tumor model","volume":"52","author":"Ghanta","year":"1974","journal-title":"J. Nat. Cancer Inst"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0315","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-197505000-00004","article-title":"The bone marrow in multiple myeloma: Correlation of plasma cells ultra structure and clinical state","volume":"54","author":"Graham","year":"1975","journal-title":"Medicine"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0320","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V62.1.166.166","article-title":"Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"62","author":"Greipp","year":"1983","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V54.1.13.13","article-title":"Improved survial of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A Study of the CALGB","volume":"54","author":"Harley","year":"1979","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0330","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.1969.tb00440.x","article-title":"Immunochemical classes of myelomatosis","volume":"16","author":"Hobbs","year":"1969","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0335","first-page":"323","article-title":"Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: Relationship to radiation dose absorbed by marrow","volume":"69","author":"Ichimaru","year":"1982","journal-title":"J. Nat. Cancer Inst"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0340","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1749-6632.1971.tb13560.x","article-title":"Pathologic conditions associated with plasma cell dyscrasias. A study of 806 cases","volume":"190","author":"Isobe","year":"1971","journal-title":"Ann. N.Y. Acad. Sci"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0345","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1097-0142(197901)43:1<124::AID-CNCR2820430119>3.0.CO;2-N","article-title":"Sequential hemi-body radiotherapy in advanced multiple myeloma","volume":"43","author":"Jaffe","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0350","first-page":"65","article-title":"Dialysis in the treatment of multiple myeloma","volume":"55","author":"Johnson","year":"1980","journal-title":"Mayo Clin. Proc"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0355","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00005792-198009000-00005","article-title":"Multiple myeloma: A clinicopathologic study of 62 consecutively autop-sied cases","volume":"59","author":"Kapadia","year":"1980","journal-title":"Medicine (Balt.)"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0360","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V57.5.813.813","article-title":"Hodgkin's disease: Biology, treatment, prognosis","volume":"57","author":"Kaplan","year":"1981","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0365","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.1983.1.12.810","article-title":"The influential T cell in B-cell neoplasms","volume":"1","author":"Kay","year":"1983","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1212\/WNL.31.1.24","article-title":"The spectrum ofperiphreal neuropathy in myeloma","volume":"31","author":"Kelly","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0375","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1212\/WNL.33.2.202","article-title":"Osteosclerotic myeloma and peripheral neuropathy","volume":"33","author":"Kelly","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0380","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: Review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin. Proc"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0385","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0390","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0308-2261(21)00325-8","article-title":"Monoclonal gammopathy of undetermined significance (MGUS): A review","volume":"11","author":"Kyle","year":"1982","journal-title":"Clin. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0395","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","article-title":"Amyloidosis: Review of 236 cases","volume":"54","author":"Kyle","year":"1975","journal-title":"Medicine (Balt.)"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0400","first-page":"751","article-title":"Management and prognosis of multiple myeloma","volume":"51","author":"Kyle","year":"1976","journal-title":"Mayo Clin. Pore"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0405","first-page":"1265","article-title":"Multiple myeloma resistant to melphalan treatment with cyclophosphamide, prednisone and BCNU","volume":"63","author":"Kyle","year":"1979","journal-title":"Cancer Treat. Rep"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0410","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0415","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM198203113061002","article-title":"\"Idiopathic\" Bence-Jones proteinuria. Long-term follow up in seven patients","volume":"306","author":"Kyle","year":"1982","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0420","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/1097-0142(19800401)45:7<1669::AID-CNCR2820450724>3.0.CO;2-5","article-title":"Effect of sodium fluoride, calcium carbonate and vitamin D on the skeleton in multiple myeloma","volume":"45","author":"Kyle","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0425","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia: Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0430","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0002-9343(80)90014-5","article-title":"Pneumococcal vaccination: The response of patients with multiple myeloma","volume":"69","author":"Lazarus","year":"1980","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0435","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0272-6386(83)80093-6","article-title":"Long-term survival of patients with multiple myeloma and acute renal failure at presentation","volume":"11","author":"Lazarus","year":"1983","journal-title":"Am. J. Kidney Dis"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0440","series-title":"Controversies in Oncology","first-page":"61","article-title":"Intensive treatment of multiple myeloma","author":"Lee","year":"1982"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0445","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C","article-title":"High dose cyclophosphamide: An effective treatment for advanced refractory multiple myeloma","volume":"53","author":"Lenhard","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0450","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/0002-9343(68)90092-2","article-title":"Immunofluorescent studies of the myeloma kidney with special reference to light chain disease","volume":"44","author":"Levi","year":"1968","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0455","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(197908)44:2<630::AID-CNCR2820440233>3.0.CO;2-G","article-title":"Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinuria disorders","volume":"44","author":"Liang","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0460","first-page":"191","article-title":"T-lymphocyte subsets in multiple myeloma patients with active and stable disease","volume":"1","author":"Ludwig","year":"1982","journal-title":"Proc. Am. Soc. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0465","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-065X.1979.tb00298.x","article-title":"Immunoregulation of murine myeloma cell growth and differentiation: A monoclonal model of B-cell differentiation","volume":"48","author":"Lynch","year":"1979","journal-title":"Immunol. Rev"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0470","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archinte.1970.00310100106014","article-title":"Meningeal myeloma","volume":"126","author":"Maldonado","year":"1970","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0475","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0002-9343(74)90164-8","article-title":"Familial myeloma. Report of eight families and a study of serum proteins in their relatives","volume":"57","author":"Maldonado","year":"1974","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0480","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High dose intravenous melphalan for plasma cell leukemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0485","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V60.4.851.851","article-title":"Myeloma protein kinetics following chemotherapy","volume":"60","author":"McGlaughlin","year":"1982","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0490","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.1973.tb05733.x","volume":"24","year":"1973","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0495","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0308-2261(21)00322-2","article-title":"Idiotype-bearing lymphoid cells in plasma cell neoplasia","volume":"11","author":"Mellstedt","year":"1982","journal-title":"Clin. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0500","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V55.6.1011.1011","article-title":"A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients","volume":"55","author":"Merlini","year":"1980","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0505","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0002-9343(72)90010-1","article-title":"Current patterns of infection in multiple myeloma","volume":"52","author":"Meyers","year":"1972","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0510","first-page":"191","article-title":"Hemi-body irradiation in multiple myeloma relapsing after or resistant to chemotherapy","volume":"1","author":"Mill","year":"1982","journal-title":"Proc. Am. Soc. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0515","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/1097-0142(19800215)45:4<647::AID-CNCR2820450405>3.0.CO;2-E","article-title":"The role of radiation therapy in the management of plasma cell tumors","volume":"45","author":"Mill","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0520","series-title":"Progress in Myeloma: Biology of Myeloma","first-page":"263","article-title":"Genetic considerations in plasmacy tomas of BALB\/c, NZB and (BALB\/c x NZB) F1 mice","author":"Morse","year":"1980"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0525","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of anosteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0530","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2141.1981.tb07273.x","article-title":"T-cell subpopulations in multiple myeloma: Correlation with clinical disease status","volume":"49","author":"Oken","year":"1981","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0535","first-page":"186","article-title":"The contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma","volume":"1","author":"Oken","year":"1982","journal-title":"Proc. Am. Soc. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0540","first-page":"270","article-title":"Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma","volume":"3","author":"Oken","year":"1984","journal-title":"Proc. Am. Soc. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0545","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI110095","article-title":"Immunoregulatory T cell function in multiple myeloma","volume":"67","author":"Ozer","year":"1981","journal-title":"J. Clin. Invest"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0550","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1983.tb02074.x","article-title":"The use of dichloromethylene diphosphonate for the management of hypercalcemia in multiple myeloma","volume":"54","author":"Patterson","year":"1983","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0555","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Influence of treatment and responsestatus on infection risk in multiple myeloma","volume":"71","author":"Perri","year":"1981","journal-title":"Am. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0560","first-page":"390","article-title":"Reassessment of risk factors for infection in multiple myeloma","volume":"22","author":"Perri","year":"1981","journal-title":"Proc. Am. Assoc. Cancer. Res. and Am. Soc. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0565","first-page":"512519","article-title":"Enhanced T cell suppression is directed toward sensitive circulatory B cells in multiple myeloma","volume":"99","author":"Perri","year":"1982","journal-title":"J. Lab. Clin. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0570","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7326\/0003-4819-77-6-853","article-title":"Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma","volume":"77","author":"Pruzanski","year":"1972","journal-title":"Ann. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0575","doi-asserted-by":"crossref","first-page":"551","DOI":"10.7326\/0003-4819-76-4-551","article-title":"Bone healing in multiple myeloma with melphalan chemotherapy","volume":"76","author":"Rodriguez","year":"1972","journal-title":"Ann. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0580","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1126\/science.7079737","article-title":"Identification of the constant chromosome regions involved in human hematologic malignant disease","volume":"216","author":"Rowley","year":"1982","journal-title":"Science"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0585","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archinte.1981.00340090048012","article-title":"Decreasing M-spike with increasing tumor burden in multiple myeloma","volume":"141","author":"Sahasrabudhe","year":"1981","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0590","first-page":"135","article-title":"Immunoglobulin synthesis and tumor kinetics of multiple royeloma","volume":"10","author":"Salmon","year":"1973","journal-title":"Semin. Hematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0595","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0308-2261(21)00321-0","article-title":"In vitro cloning and chemosensitivity of human myeloma stem cells","volume":"11","author":"Salmon","year":"1982","journal-title":"Clin Haem"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0600","series-title":"Textbook of Medicine","article-title":"Plasma cell disorders","author":"Salmon","year":"1982"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0605","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1983.1.8.453","article-title":"Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group study","volume":"1","author":"Salmon","year":"1983","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0610","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(74)90748-X","article-title":"B-cell neoplasia in man","volume":"2","author":"Salmon","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0615","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1172\/JCI106327","article-title":"Immunoglobulin synthesis and total body cell number in IgG multiple myeloma","volume":"49","author":"Salmon","year":"1970","journal-title":"J. Clin. Invest"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0620","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","article-title":"Biphasic pattern of bacterial infection in multiple myeloma","volume":"96","author":"Savage","year":"1982","journal-title":"Ann. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0625","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000225611","article-title":"Changing patterns of infection in patients with multiple myeloma","volume":"39","author":"Shaikh","year":"1982","journal-title":"Oncology"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0630","first-page":"215","article-title":"Continuous infusion vincristine and Adria mycin plus high-dose dexamethasone. A highly effective salvage regimen for patients with previously treated myeloma","volume":"62","author":"Smith","year":"1983","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0635","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archinte.1980.00330140114029","article-title":"Meningeal myelomatosis","volume":"140","author":"Spiers","year":"1980","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0640","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01857369","article-title":"Treatment of lymphoid tumors with anti-idi-otype antibodies","volume":"6","author":"Stevenson","year":"1983","journal-title":"Semin. Immunopathol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0645","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2141.1974.tb06775.x","article-title":"Hyperviscosity syndrome in IgA multiple myeloma","volume":"27","author":"Tuddenham","year":"1974","journal-title":"Br. J. Haematol"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0650","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archinte.1973.03650100076014","article-title":"Infections complicating multiple myeloma and chronic lymphcytic leukemia","volume":"132","author":"Twomey","year":"1973","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0655","first-page":"739","article-title":"Scintigraphic evaluation of the skeleton in multiple myeloma","volume":"55","author":"Wahner","year":"1980","journal-title":"Mayo Clin. Proc"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0660","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann","year":"1969","journal-title":"Progr. Allergy"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0665","first-page":"169A","article-title":"Failure of cyclophosphamide to produce response in melphalan-resistant multiple myeloma","volume":"58","author":"White","year":"1981","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0670","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00005792-197605000-00002","article-title":"The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis","volume":"55","author":"Wiltshaw","year":"1976","journal-title":"Medicine"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0675","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V52.4.839.839","article-title":"Plasma cell leukemia (PCL): A report on 15 patients","volume":"52","author":"Woodruff","year":"1978","journal-title":"Blood"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0680","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.6336310","article-title":"The chromosonal basis of human neoplasia","volume":"221","author":"Yunis","year":"1983","journal-title":"Science"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0685","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","article-title":"Distinctive chromosonal abnormalities in histologic subtypes of non-Hodgkin's Lymphoma","volume":"307","author":"Yunis","year":"1982","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0025-7125(16)31127-0_bib0690","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.7326\/0003-4819-41-6-1152","article-title":"Recurrent pneumonia in multiple myeloma and some observations on immunologic response","volume":"41","author":"Zinneman","year":"1954","journal-title":"Ann. Intern. Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516311270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516311270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T06:30:16Z","timestamp":1748845816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712516311270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,5]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984,5]]}},"alternative-id":["S0025712516311270"],"URL":"https:\/\/doi.org\/10.1016\/s0025-7125(16)31127-0","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[1984,5]]}}}